Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Crossref DOI link: https://doi.org/10.1186/s40425-016-0177-2
Published Online: 2016-11-15
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Agrawal, Shruti
Feng, Yan
Roy, Amit
Kollia, Georgia
Lestini, Brian
Funding for this research was provided by:
Bristol-Myers Squibb (Not applicable)